Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.44
- Piotroski Score 2.00
- Grade Neutral
- Symbol (ZURA)
- Company Zura Bio Limited
- Price $2.91
- Changes Percentage (0.34%)
- Change $0.01
- Day Low $2.91
- Day High $2.99
- Year High $6.35
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $15.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.65
- Trailing P/E Ratio 6.17
- Forward P/E Ratio 6.17
- P/E Growth 6.17
- Net Income $-60,360,000
Income Statement
Quarterly
Annual
Latest News of ZURA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sage Therapeutics/Biogen's episodic therapy zuranolone could change MDD treatment
Sage Therapeutics and Biogen's zuranolone, a novel antidepressant for MDD, showed positive results in a Phase III trial. The drug's rapid response treatment offers a new mechanism of action in a compe...
By Yahoo! Finance | 4 months ago -
Zura Bio Shares Fall on Warrant Exchange Offer to Simplify Capital Structure
Zura Bio's shares declined as the company initiated a warrant exchange offer to simplify its capital structure and reduce dilution. The stock fell 2.9% to $3.64, down 22% year-to-date and 42% in the p...
By MarketWatch | 4 months ago
